Skip to main content

You are here

Home » Public Health Programs » Infectious Diseases » Antimicrobial Resistance Laboratory Network

Antimicrobial Resistance Laboratory Network

Application period now open for the 2019-2020 Association of Public Health Laboratory (APHL) - CDC Fellowships to be hosted at the Wadsworth Center.

ARLN Regional Lab testing takes place in both the Bacteriology Laboratory and the Mycology Laboratory (Candida)

Northeast Regional Isolate Submission (CT, ME, MA, NH, NJ, RI, VT and NYC)

  • Submit discordant CRE/CRPA after initial testing, pan-resistant CRE/CRPA, MDR Acinetobacter baumanii, emerging antibiotic-resistant bacteria including mcr-1 and mcr-2 containing bacteria.
  • Complete the Infectious Diseases Requisition Form. (Please fill in “AMR ID” in the other section.) 

New York State Isolate Submission 

  • NYS CRE/CRPA isolate submission should include CRE, CRPA, pan-resistant CRE/CRPA, MDR Acinetobacter baumanii, emerging antibiotic-resistant bacteria including mcr-1 and mcr-2 containing bacteria.
  • Complete the Infectious Diseases Requisition Form. (Please fill in “AMR ID” in the other section.)

ARLN Regional CRE Colonization Submission

*Preapproval of testing is required. Contact the ARLN Core. 

Learn more about the role of Wadsworth Center's ARLN Core in the national Antimicrobial Resistance Laboratory Network.

 

Antimicrobial Resistance Laboratory Network Workshop

Program Updates

Souvenirs

Souvenirs: What did you bring home from your last trip to the hospital?

The stuff we carry around says a lot about us. If I were to dump my purse right now, you'd find a shell from my last trip to the ocean, a garnet from a hike up north and a penny pressed from an amusement park. Bacteria tell us a lot about themselves from the stuff (genes) they carry around as...

read more
AR Lab Network

Fighting Antibiotic Resistance with Printing Technology

Wadsworth Center's Antibiotic Resistance (AR) Regional Laboratory was chosen by CDC as one of four labs in the AR Lab Network to serve as a pilot site, "printing" with new drugs rather than...

read more